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Abstract: The prognosis of patients with advanced melanoma has improved dramatically. However,
the clinical outcomes of patients with highly elevated serum lactate dehydrogenase (LDH) remain
very poor. The aim of this study was to explore whether patients with normalized LDH after
targeted therapy could benefit from subsequent treatment with immune checkpoint inhibitors (ICI).
Data from all patients with BRAF-mutant metastatic melanoma with a highly elevated serum LDH
at baseline (≥2× upper limit of normal) receiving first-line targeted therapy between 2012 and 2019
in The Netherlands were collected. Patients were stratified according to response status to targeted
therapy and change in LDH at start of subsequent treatment with ICI. Differences in overall survival
(OS) between the subgroups were compared using log-rank tests. After a median follow-up of
35.1 months, median OS of the total study population (n = 360) was 4.9 months (95% CI 4.4–5.4). Of all
patients receiving subsequent treatment with ICI (n = 113), survival from start of subsequent treatment
was significantly longer in patients who had normalized LDH and were still responding to targeted
therapy compared to those with LDH that remained elevated (median OS 24.7 vs. 1.1 months).
Our study suggests that introducing ICI upon response to targeted therapy with normalization of
LDH could be an effective strategy in obtaining long-term survival in advanced melanoma patients
with initial highly elevated serum LDH.
Keywords: melanoma; metastasis; targeted therapy; immune checkpoint inhibitors;
lactate dehydrogenase; real-life data; prognostic factors
1. Introduction
Multiple effective systemic treatment options have emerged for patients with advanced
BRAF-mutant melanoma over the last decade. Since the approval of the BRAF inhibitor vemurafenib [1]
and the CTLA-4 antibody ipilimumab [2], combination therapy with a BRAF and MEK inhibitor [3] and
treatment with anti-PD-1 antibodies as monotherapy [4,5] or combined with a CTLA-4 antibody [6]
have broadened the therapeutic arsenal for these patients. Combination therapy with a BRAF and
MEK inhibitor has resulted in a median overall survival of over two years [7], while treatment with
anti-PD-1 also concurrently showed significant improvements, with 2-year survival rates of 55–58% [8].
Nevertheless, although long-term survival may be achieved in a subgroup of patients, there is still an
unmet medical need for patients with unfavorable prognostic factors [7,9]. Elevated serum lactate
dehydrogenase (LDH) level is a well-known marker for poor outcome, and a strong negative predictor
for response to immune checkpoint inhibitors (ICI) and targeted therapy [7,8]. In previous reports,
substantially less activity was demonstrated in patients with elevated serum LDH of ≥2× upper limit
of normal (ULN), with a median OS of 2.9 months after ipilimumab therapy [9] and 2.3 months after
anti-PD1 therapy [10]; compared to 14.7 months and 16.1 months for patients with normal LDH,
respectively. Similarly, LDH has been shown to be one of the key predictors of survival for patients
receiving targeted therapy [11]. Although the majority of BRAF mutant patients with elevated serum
LDH respond to targeted therapy, responses are usually short-lived, with median progression-free
survival shorter than six months for patients with LDH ≥2× ULN, compared to 17 months for the
patients with normal LDH [7].
Targeted therapies are capable of inducing rapid anti-tumor responses associated with a decrease
in LDH [7], which might enable ICI to work more efficiently in patients with initial elevated serum
LDH. Furthermore, BRAF and MEK-inhibition could facilitate immune responses in multiple ways.
Preclinical data showed an increase in CD8+ T-cell recognition of tumor cells by inducing rapid
upregulation of MHC class I surface expression in BRAF-mutant melanoma cells [12,13]. These data
support the potential of BRAF-inhibition to increase response rates to ICI. Although this concept seems
promising, clinical data supporting the approach of BRAF inhibitor induction treatment preceding
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treatment with ICI in patients with aggressive disease are lacking, and little is known about which
patients could benefit from induction treatment.
This prospective population-based study focuses on the clinical outcomes of BRAF-mutant
metastatic melanoma patients with baseline serum LDH of ≥2× ULN treated with first-line targeted
therapy. The main objective of the study was to investigate whether the level of LDH and response
status at the switch to ICI was associated with survival.
2. Results
2.1. Overall Study Population
A total of 5639 unresectable stage IIIC or IV melanoma patients were registered in the Dutch
Melanoma Treatment Registry (DMTR) between 1 July, 2012 and 1 June 1, 2019 (Figure 1). Of these, 360
BRAF-mutant advanced melanoma patients with a baseline serum LDH of ≥2× ULN received first-line
targeted therapy and were included for analyses. Baseline characteristics are shown in Table 1. The
median age was 60 years and the majority of patients were male (60%). Median serum LDH was 823
U/L (IQR 625–1419). Thirty eight percent of patients had an Eastern Cooperative Oncology Group
performance status (ECOG PS) of ≥2 and most patients had ≥3 organ sites involved (72%). The majority
of patients received BRAF monotherapy (76%). BRAF monotherapy was mainly prescribed up to
August 2016. Combination therapy with a BRAF- and MEK inhibitor was increasingly used since
October 2015. Median follow-up was 35.1 months (95% CI 18.2–52.1) and 308 patients (85%) died
during follow-up. At time of analysis, 91% of patients discontinued treatment with targeted therapy,
due to disease progression (60%), toxicity (10%), death (9%), planned in advance (11%), patient’s choice
(2%), other (4%) and unknown (4%).
Figure 1. Flowchart of study population.
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Median baseline LDH (IQR) 823 (625–1419)














Type of targeted therapy
BRAFi monotherapy 206 (76)
BRAFi + MEKi 154 (24)
IQR = interquartile range; ECOG PS = Eastern Cooperative Oncology Group performance status; BRAFi = BRAF
inhibitor; MEKi = MEK inhibitor.
Median OS was 4.9 months (95% CI 4.4–5.4) (Figure 2). Survival rates at six months and one year
were 40% (95% CI 35–45) and 16% (95% CI 12–20), respectively.
Figure 2. Overall survival of study population.
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2.2. Patients with Subsequent Treatment with ICI
A total of 113 patients (31%) received subsequent treatment with ICI. Combination therapy of
ipilimumab and nivolumab was most often administered (n = 55), followed by anti-PD1 (pembrolizumab
(n = 20), nivolumab (n = 16)), and ipilimumab (n = 22). Baseline characteristics at start of subsequent
treatment with ICI are shown in Table 2. Median follow up from start of subsequent treatment with
ICI was 30.0 months (95% CI 10.6–51.2).















≥1 to <2× ULN 42 (37)




















Type of prior targeted therapy
BRAFi monotherapy 41 (36)
BRAFi + MEKi 72 (64)
Response on targeted therapy
Partial response 27 (24)
Stable disease 7 (6)
Progressive disease 79 (70)




Ipilimumab and nivolumab 55 (49)
ECOG PS = Eastern Cooperative Oncology Group performance status; BRAFi = BRAF-inhibitor; MEKi = MEK
inhibitor. LDH = lactate dehydrogenase, ULN = upper limit of normal; ICI = immune checkpoint inhibitors.
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The main objective of the study was to investigate whether the response to targeted therapy
and level of serum LDH at start of subsequent treatment with ICI affects survival. Outcomes were
stratified according to LDH at start of subsequent treatment with ICI and tumor response after targeted
therapy. Table 3 shows the median OS and 6-months survival rates, calculated from start of subsequent
treatment with ICI.
Table 3. Kaplan–Meier estimates of median overall survival, and 6-months and 1-year survival rates at
start of subsequent treatment with ICI, according to serum LDH at start of subsequent treatment with







Median OS 6 m Survival Rate 1 y Survival Rate
(95% CI), m (95% CI), % (95% CI), %
<ULN
PR 7/16 24.7(16.1–33.4) 85 (66–100) 73 (46–100)
SD 5/6 7.0 (0–14.9) 63 (21–100) 21 (0–57)
PD 14/16 4.4 (1.3–7.4) 36 (11–61) 22 (0–44)
≥1 to <2× ULN a
PR 5/9 10.4 (0–22.5) 60 (24–96) 40 (0–80)
PD 25/32 2.7 (1.9–3.5) 24 (8–40) 20 (5–35)
≥2× ULN b
PD 29/31 1.1 (0.7–1.6) 17 (3–30) 8 (0–19)
LDH = lactate dehydrogenase, ULN = upper limit of normal, ICI = immune checkpoint inhibitors, OS = overall
survival, m = months, NR = not reached, PR = partial response, SD = stable disease, PD = progressive disease. a
Due to low numbers of patients with stable disease (n = 1) in this subgroup, these patients were excluded from
analyses. b Due to low numbers of patients with partial response (n = 2) in this subgroup, these patients were
excluded from analyses.
Patients with a normalized LDH who had a partial response to prior targeted therapy (n = 16;
combination therapy of BRAF and MEK inhibitor (n = 11), BRAF monotherapy (n = 5)) had the best
survival from start of treatment with ICI (median OS 24.7 (95% CI 16.1–33.4) and 6-months and 1-year
survival rate of 85% (95% CI 66–100) and 73% (95% CI 46–100), respectively). In this subgroup, most
patients received combination therapy of ipilimumab and nivolumab (n = 9), followed by anti-PD1
(n = 6) and ipilimumab (n = 1). Median duration of targeted therapy before switching to ICI in
LDH-normalized patients was 3.6 months (range 1.8–30.9). The main reason for treatment switch to
ICI was a planned switch (n = 9). Other reasons were toxicity (n = 3) and unknown (n = 4). Baseline
characteristics at start of targeted therapy were compared between the subgroup with normalized
LDH and partial response, and the other subgroups. No significant differences were found (Table S1).
Most patients who had an elevated LDH at start of treatment with ICI had progressed on targeted
therapy (n = 63). Median duration of targeted therapy before switching to ICI was 5.9 months (95%
CI 5.3–6.6). Patients who started second-line ICI with LDH ≥ 2× ULN had the worst outcomes, with
a median OS of 1.1 months (95% CI 0.7–1.6), and 6-months and 1-year survival rate of 17% (95%
CI 3–30) and 8% (95% CI 0–19), respectively. The survival curves demonstrate significant survival
differences between the normalized LDH group with partial response, compared to the other subgroups
(Figure 3a,b).
The 6-months and 1-year survival rates of the subgroup with normalized LDH and partial response
are significantly better when compared to the whole subgroup that received ICI (6 months: 85% (95%
CI 66–100) vs. 31% (95% CI 21–41); and 1-year: 73% (95% CI 46–100) vs. 18 (95% CI 10–27)).
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Figure 3. Differences in Kaplan–Meier curves of overall survival at start of subsequent treatment with
ICI, in the subgroup with normalized LDH and PR compared to (A) normalized LDH and SD or PD,
(B) all other subgroups, LDH = lactate dehydrogenase, OS = overall survival, CI = confidence interval,
PR = partial response, SD = stable disease, PD = progressive disease.
3. Discussion
These real-world data support previous reports of the poor prognosis of advanced melanoma
patients with highly elevated serum LDH. At the same time, these data provide a potential strategy
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to improve clinical outcomes. In our cohort of metastatic melanoma patients with baseline serum
LDH of ≥2x ULN treated with first-line BRAF(/MEK) inhibitors, median OS was significantly longer in
patients with normalized LDH and still responding to initial targeted therapy who started second-line
treatment with ICI, compared to those with elevated LDH at start of treatment with ICI. Our data
suggest that introducing ICI upon response to targeted therapy with normalization of LDH could be
an effective strategy in obtaining long-term survival in patients with initial elevated serum LDH.
The median OS of 4.9 months of the overall study population confirms previous data, as clinical
outcomes remain poor in this subgroup of patients [9,10,14]. Patients who received subsequent
treatment with ICI with LDH levels that remained ≥2× ULN are unlikely to benefit from ICI with a
median OS of 1.1 months and a 6-months and 1-year survival rate of 17% and 8%, respectively.
The exact role of LDH is not completely elucidated. It could simply be a marker of more aggressive
disease that requires rapid anti-tumor responses [9]. The delayed tumor responses generally observed
with ICI might therefore take too long for these patients to benefit. Moreover, tumor metabolism is
characterized by the conversion of pyruvate into lactate, even in the presence of sufficient oxygen.
Preclinical data demonstrated that tumor cells producing high levels of lactic acid disturb the function
of cytotoxic T lymphocytes, thereby negatively influencing the potency of an immune response [15,16].
Interestingly, our data show that patients who switch to ICI with normalized LDH while still
responding to targeted therapy have a real chance of long-term survival. After a median follow-up of
30 months, median OS was 24.7 months, and 6-months and 1-year survival rate was 85% and 73%,
respectively. Survival was significantly longer compared to the other subgroups. No differences were
found in prognostic factors at start of targeted therapy among the subgroups, indicating that this
subgroup is not simply a selection of a best prognosis group.
It should be noted that only a small proportion of patients received this treatment strategy (n = 16;
4% of total study population). However, the majority of the total study population (n = 360) received
BRAF monotherapy as first-line targeted therapy. The emergence of combination therapy with a BRAF
and MEK inhibitor for this subgroup of patients might lead to a greater proportion of patients with
response to targeted therapy and normalization of LDH. A 3-year follow-up pooled analysis of phase
III trials with BRAF and MEK inhibitor combination therapy showed promising results, with 50%
partial response in patients with initial LDH ≥ 2× ULN [17].
The value of sequencing targeted therapy prior to treatment with ICI in patients with initial elevated
LDH has not been investigated thus far. Previous retrospective reports revealed that normalization of
LDH while on targeted therapy was associated with ipilimumab cycle completion [18,19]. In another
study on 101 advanced melanoma patients with decreased serum LDH after BRAF inhibitor treatment
who completed all courses of ipilimumab, showed a significantly longer OS compared to those who
did not (median OS 12.7 months vs. 1.2 months) [20].
The real benefit of induction treatment with combined BRAF- and MEK-inhibition in patients with
elevated LDH is currently under investigation in multiple prospective randomized trials. The EORTC
EBIN study (NCT03235245), compares ipilimumab and nivolumab upfront versus the same treatment
preceded by induction therapy with encorafenib and binimetinib in advanced melanoma patients,
irrespective of LDH level. One of the arms of the three-arm phase II SECOMBIT study (NCT02631447)
will assess whether an induction treatment with encorafenib plus binimetinib of 8 weeks before
combination therapy with ICI might help potentiate an immunotherapeutic response. Guidelines are
not conclusive on this issue. Our results may therefore be of added value to medical oncologists while
awaiting these trial results.
It would be interesting to investigate survival differences between patients who started second-line
treatment with ICI with normalized LDH and response to initial targeted therapy vs. responders who
stayed on targeted therapy. Unfortunately, this could not be assessed with our data, as we have no
information on LDH level during follow-up with patients who stayed on targeted therapy.
Given the observational design of this analysis, we cannot rule out confounding by indication or
selection bias. However, its multicentered design attenuates this potential selection bias. Furthermore,
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observational studies are more susceptible to registration bias. To ensure high-quality data,
data managers were extensively trained and supervised by oncologists [21]. Another limitation
is the small number of patients in the subgroup analyses. The conclusions drawn need validation in
prospective randomized trials. Lastly, other clinical parameters such as lymphocyte counts and CRP
level that have also been associated with patient outcome after treatment with ICI were not registered
in our database, and could therefore not be included in this study [16].
4. Materials and Methods
4.1. Data: The Dutch Melanoma Treatment Registry (DMTR)
Data were retrieved from the Dutch Melanoma Treatment Registry (DMTR), a prospective
population-based registry that was set-up to monitor the safety and effectiveness of the new drugs in
real-world clinical practice and to assess the quality of melanoma care in The Netherlands. The DMTR
contains information on baseline patient and tumor characteristics, local and systemic treatment
modalities, treatment-related adverse events (grade 3 or 4 according to common terminology criteria
for adverse events (CTCAE) version 4), and clinical outcomes of all patients with unresectable stage
IIIC or IV melanoma. A detailed description of the DMTR was published previously [21].
In compliance with Dutch regulations, the DMTR was approved by the medical ethical committee
and was not subject to the Medical Research Involving Human Subjects Act. Patients were offered an
opt-out option.
4.2. Patients
All patients with BRAF-mutant unresectable or metastatic (stage IIIC or stage IV) cutaneous
melanoma or with a BRAF-mutant melanoma of unknown primary with a baseline serum LDH of ≥2x
the upper limit of normal (ULN), who received targeted therapy (either monotherapy with a BRAF
inhibitor or combination therapy with BRAF and MEK inhibitors) between 1 July, 2012 and 1 June,
2019 were included. The ULN was defined at 250 U/L. Patients with prior systemic treatment for
metastasized disease were excluded to avoid bias of ongoing activity of previous systemic agents.
4.3. Statistical Analysis
Time to next treatment (TTNT) and overall survival (OS) with corresponding two-sided 95%
confidence intervals (CI) for medians were analyzed using the Kaplan–Meier method. For the overall
study population, TTNT was determined from the start of targeted therapy to the start of subsequent
systemic therapy, or death from any cause. Patients who were still on treatment were censored at time
of analysis. OS was defined as the time from start of targeted therapy to the date of death from any
cause. Patients alive at time of analysis were censored. Follow-up time was calculated from start date
of targeted therapy using the inverse Kaplan–Meier method [22].
The main objective of the study was to investigate whether the response to targeted therapy
and level of serum LDH at start of subsequent treatment with ICI affects survival. For this analysis,
OS was defined from start of subsequent treatment with ICI to the date of death from any cause.
Patients were stratified according to LDH at start of subsequent treatment with ICI (<ULN, >1 to
<2× ULN, ≥2× ULN) and tumor response after treatment of targeted therapy according to Response
Evaluation Criteria in Solid Tumors (RECIST). OS was compared between the subgroups using log-rank
tests. Statistical significance was defined as a two-sided p value < 0.05. All statistical analyses were
performed in PASW Statistics version 20 (SPSS Inc. Chicago, IL, USA).
5. Conclusions
This population-based study confirms the very poor prognosis of advanced melanoma patients
with LDH ≥ 2× ULN. Moreover, our data suggest that switching to ICI upon response to targeted
therapy with normalization of LDH may be a strategy to obtain long-term survival for these patients.
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Nevertheless, randomized trials are needed to assess the real benefit of sequential treatment of targeted
therapy and ICI in patients with highly elevated serum LDH.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/11/12/1940/s1,
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LDH and PR (n = 16) and all other groups (n = 97) after targeted therapy.
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